FindMyKOL
Clinical trialNCT00802685TerminatedInterventional

Timing of PDA Closure and Respiratory Outcome in Premature Infants

NCT00802685 is an interventional trial sponsored by University of Miami. As of 21 Nov 2026, it was terminated. It studies Early ibuprofen in Patent Ductus Arteriosus. The registry lists an enrollment of 105 participants at 1 site in 1 country. The registry lists a start date of 30 Nov 2007 and a primary completion date of 31 Aug 2010.

SponsorUniversity of Miami →Enrollment105Patent Ductus Arteriosus
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00802685
FieldValue
Registry IDNCT00802685
StatusTerminated
Study typeInterventional trial
Lead sponsorUniversity of Miami
Enrollment105
Registered sites1
Countries1
ConditionsPatent Ductus Arteriosus
DrugsEarly ibuprofen
Start30 Nov 2007
Primary completion31 Aug 2010
Study completion28 Feb 2011
Last update posted5 Feb 2014

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The investigators propose the present study with the following aims: * to determine whether early patent ductus arteriosus (PDA) treatment with ibuprofen treatment at the onset of clinical symptoms is superior to late ibuprofen treatment only when symptoms of a hemodynamically significant PDA are present in the evolution of bronchopulmonary dysplasia (BPD) defined as duration of supplemental oxygen exposure during the first 28 days * to determine whether early PDA treatment with ibuprofen will be superior to late treatment with ibuprofen in efficacy of PDA closure, need for rescue therapy, need for PDA ligation and incidence of major complications of prematurity. Hypothesis: Early pharmacologic closure of PDA with ibuprofen will improve respiratory course and reduce BPD as reflected by a reduction in duration of supplemental oxygen during the first 28 days of age vs. late pharmacologic treatment with ibuprofen. Outcome variables: The primary outcome of this study is the number of days spent on supplemental oxygen by each infant during the first 28 days. Other outcomes to be determined between groups include: * Mortality * Other respiratory variables: total days on supplemental oxygen, days on mechanical ventilation, oxygen dependence at 36 weeks post menstrual age, age at final extubation. * Other respiratory complications: pneumothorax, pulmonary interstitial emphysema, need for high frequency ventilation, pulmonary hypertension * Efficacy of PDA closure: number of courses of medication required, need for ligation * Other neonatal complications: intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), intestinal perforation, sepsis, renal dysfunction (oliguria, elevated creatinine) * Time to achieving full enteral feedings, time to regain birth weight, weight at discharge. * Length of hospital stay

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • Jackson Memorial Hospital/holtz Children's Center

    Miami

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Early ibuprofen
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00802685

Each answer restates registry values shown on this page.

What is NCT00802685?

NCT00802685 is an interventional trial sponsored by University of Miami. It studies Early ibuprofen in Patent Ductus Arteriosus.

Who leads NCT00802685?

The registry names Ilene RS Sosenko, MD (principal investigator, University of Miami) as the overall official.

Where does NCT00802685 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00802685 study?

The registered drug and biological interventions are Early ibuprofen.

When did NCT00802685 end?

The registry lists a primary completion date of 31 Aug 2010 and a study completion date of 28 Feb 2011. The sponsor last updated the record on 5 Feb 2014.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.